Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Galapagos (GLPG) and Pharvaris (PHVS)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ligand Pharma (LGND – Research Report), Galapagos (GLPG – Research Report) and Pharvaris (PHVS – Research Report).

Ligand Pharma (LGND)

In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Ligand Pharma. The company’s shares closed last Friday at $68.01.

According to TipRanks.com, Hewitt is a 4-star analyst with an average return of 9.8% and a 47.1% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Streamline Health Solutions, Surgalign Holdings, and Champions Oncology.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ligand Pharma with a $117.00 average price target, a 72.5% upside from current levels. In a report issued on July 25, Barclays also maintained a Buy rating on the stock with a $110.00 price target.

See the top stocks recommended by analysts >>

Galapagos (GLPG)

In a report released today, James Quigley from Morgan Stanley maintained a Hold rating on Galapagos, with a price target of $42.00. The company’s shares closed last Friday at $41.82.

According to TipRanks.com, Quigley is a 3-star analyst with an average return of 2.0% and a 49.3% success rate. Quigley covers the Healthcare sector, focusing on stocks such as Kymera Therapeutics, Morphosys Ag, and Evotec AG.

Galapagos has an analyst consensus of Hold, with a price target consensus of $48.50.

Pharvaris (PHVS)

In a report released today, Matthew Harrison from Morgan Stanley maintained a Hold rating on Pharvaris, with a price target of $10.00. The company’s shares closed last Friday at $16.91.

According to TipRanks.com, Harrison is a 5-star analyst with an average return of 7.7% and a 51.2% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Sigilon Therapeutics, and Bristol-Myers Squibb.

Currently, the analyst consensus on Pharvaris is a Hold with an average price target of $14.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on LGND:

• Ligand says Merck reports V116 met key endpoints in two Phase 3 trials
• Ligand price target lowered to $110 from $120 at Barclays
• Ligand offers to acquire Novan for $15M in cash, $15M in financing
• Novan to sell substantially all assets for $15M, files for Chapter 11 protection
• Biotech Alert: Searches spiking for these stocks today